contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


arcticzymes-technologies-initiates-share-buyback-to-support-employee-share-purchase-program

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.

ArcticZymes Technologies

Tromsø, Norway, November 25th, 2025 - ArcticZymes Technologies ASA (OSE: AZT) has decided to initiate a share buyback program pursuant to the authorization granted by the Annual General Meeting...

<div class="abstract">Tromsø, Norway, November 25th, 2025 - ArcticZymes Technologies ASA (OSE: AZT) has decided to initiate a share buyback program pursuant to the authorization granted by the Annual General Meeting held on&nbsp;27 May 2025</div>The purpose of the program is to settle share-based incentive programs for employees and management where employees can acquire shares at 15% discount from market price.The buyback will be carried out in accordance with Article 5 of the EU Market Abuse Regulation (MAR) and Commission Delegated Regulation (EU) 2016/1052, which provides a "safe harbour" from market manipulation rules for legitimate share repurchase program.The parameters for the program are as follows:<ul>	<li>Maximum number of shares to be acquired: 31,365 shares</li>	<li>Maximum total consideration: NOK 3.1 million</li>	<li>Purchase price per share shall be between NOK 1.00 and NOK 100.00</li>	<li>The program will be carried out during the period from 25 November 2025 to 5 December 2025</li>	<li>The repurchases will be made on the Oslo Stock Exchange and will be executed by DNB Carnegie, a part of DNB Bank ASA, independently of the Company.</li></ul>The Company will publish information about transactions carried out under the program in accordance with applicable regulations.The authorization granted by the General Meeting allows the Board of Directors to acquire up to 5% of the Company's share capital, with a nominal value per share of NOK 1.00 per share.This information is made public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.For more information, please contact:<table cellspacing="0">	<tbody>		<tr>			<td>ArcticZymes Technologies ASA</td>			<td>		</td></tr>		<tr>			<td>CEO, Michael B. Akoh</td>			<td>Tel: +46 (0) 70 262 37 15</td>		</tr>		<tr>			<td>CFO, Børge Sørvoll</td>			<td>Tel +47&nbsp;952 90187</td>		</tr>		<tr>			<td>			</td><td>ir@arcticzymes.com</td>		</tr>	</tbody></table>About ArcticZymes Technologies ASAHeadquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly listed, leading provider of novel and high-quality enzymes for use in molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company develops and manufactures salt-active nucleases and other specialty enzymes inspired by the Arctic environment, enabling robust performance under demanding process conditions. ArcticZymes is certified to ISO 13485 and manufactures under relevant ICH GMP standards.&nbsp; For more information, visit <a href="https://www.arcticzymes.com/">www.arcticzymes.com</a>.<div></div>

ArcticZymes Technologies Initiates Share Buyback to Support Employee Share Purchase Program

ArcticZymes Technologies ASA
CEO, Michael B. Akoh	Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll	Tel +47 952 90187
	ir@arcticzymes.com